Drug Profile
Norucholic acid - Dr Falk Pharma
Alternative Names: EA-3355; NorUDCA; Norursodeoxycholic acid; NUC - Dr Falk Pharma; Ursodeoxycholic acid homologueLatest Information Update: 20 May 2022
Price :
$50
*
At a glance
- Originator Dr Falk Pharma
- Developer Dr Falk Pharma; EA Pharma
- Class Anti-inflammatories; Antifibrotics; Cholic acids; Gallstone therapies; Hepatoprotectants
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Primary sclerosing cholangitis
- Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Discontinued Liver disorders
Most Recent Events
- 20 May 2022 Discontinued - Phase-I for Liver disorders (In volunteers) in Japan (PO), due to business priorities (EA Pharma, Eisai Co Ltd pipeline, May 2022)
- 07 Mar 2022 Phase-II clinical trials in Primary biliary cirrhosis (In adults, In the elderly, Treatment-experienced) in Germany (PO) (EudraCT2021-001431-56 )
- 01 Sep 2021 EA Pharma completes a phase I clinical trials in Liver disorders (In volunteers) in Japan (PO) (JapicCTI-205163)